National Cancer Institute (NCI) shared a post on LinkedIn:
“Advances in precision medicine may expand options for children with rare cancers.
NCI researchers found that targeted therapies already approved for certain adult cancers showed promise against rare RAS-mutated pediatric cancers in preclinical studies. The findings highlight the potential to repurpose existing treatments, accelerate therapeutic development, and expand options for children facing rare cancers with limited treatment choices.
This work reflects the power of combining innovative laboratory research, genomic data resources, and collaboration to advance more precise and effective treatments for patients. It also underscores the importance of ensuring that children benefit from the same scientific advances that are transforming cancer care.”
Other articles about Pediatric Cancers on OncoDaily.